Preclinical Models for Anticancer Drug Development

摘要: New molecules under consideration as novel cancer therapeutics face a number of challenges in their development path. Most prominent among these is that contrast to therapeutic areas such infectious diseases or inflammation, where variety model systems are predictive clinical success assuming pharmaceutical features the candidate can be properly designed modified, models lacking oncology. Thus, an overriding goal drug pathway should “fail fast” structures have low likelihood success, and “advance smartly” will achieve desired goal, which ultimately evolution successful registration strategy. This chapter touch on various types yardsticks applied throughout drug’s path goals.